<DOC>
	<DOCNO>NCT00383487</DOCNO>
	<brief_summary>To determine whether , patient population , treatment calcitriol Naproxen effective delaying growth prostate cancer treatment calcitriol alone see historical control .</brief_summary>
	<brief_title>A Phase II Trial Calcitriol Naproxen Patients With Recurrent Prostate Cancer</brief_title>
	<detailed_description>In summary , vitro vivo study , well early phase clinical trial , show promising role calcitriol NSAIDs treatment prostate cancer . Moreover , calcitriol NSAIDs exert antiproliferative effect decrease prostaglandin level , different mechanism . Thus , reason believe combine effect prostaglandin may synergistic . Preliminary vitro assay calcitriol give combination one two different NSAIDs ( Naprosyn sulindac ) LNCaP cell line indicate synergy . This observation provide rational use combination treatment prostate cancer . In addition , hop synergy note would allow use low dos NSAIDs .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Dihydroxycholecalciferols</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<mesh_term>Naproxen</mesh_term>
	<mesh_term>Naproxen-n-butyl nitrate</mesh_term>
	<criteria>Must give write informed consent Histologically confirm adenocarcinoma prostate Biochemical relapse primary radiation therapy surgery Normal testosterone level 3 rise PSA nadir , interval PSA determination &gt; 2 week Local recurrence CT scan Distant metastases bone scan Hypercalcemia Nephrolithiasis Renal insufficiency ( serum creatinine &gt; 1.8 mg/dl ) Pancreatitis History ulcer gastrointestinal bleeding More 6 month hormone ablation therapy Concurrent therapy prostate cancer Uncontrolled HTN H/O MI , CVA , TIA Known coronary disease/cerebrovascular disease Platelet count &lt; 50 Patients anticoagulant Patients lithium</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>